tegafur has been researched along with Drug-Induced Stevens Johnson Syndrome in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "TS-1 has been used for the treatment of gastric cancer, both in the adjuvant and metastatic setting, and is increasingly being used in other malignancies such as colon, pancreatic and non-small cell lung cancer." | 1.37 | Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer. ( Aw, CW; Lee, SC; Lim, R; Lim, TC; Tan, CS; Yeo, SW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Komatsu-Fujii, T | 1 |
| Ogawa, M | 1 |
| Nonoyama, S | 1 |
| Fukumoto, T | 1 |
| Tanabe, H | 1 |
| Tan, CS | 1 |
| Lim, R | 1 |
| Lim, TC | 1 |
| Aw, CW | 1 |
| Yeo, SW | 1 |
| Lee, SC | 1 |
| Yamazaki, Y | 1 |
| Yamada, A | 1 |
| Sugaya, S | 1 |
| Osawa, A | 1 |
3 other studies available for tegafur and Drug-Induced Stevens Johnson Syndrome
| Article | Year |
|---|---|
Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
Topics: Aged; Antineoplastic Agents, Immunological; Drug Combinations; Female; Humans; Nivolumab; Oxonic Aci | 2021 |
Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Combinations; | 2011 |
[Visual disturbance].
Topics: Antimetabolites, Antineoplastic; Antitubercular Agents; Cataract; Central Serous Chorioretinopathy; | 2012 |